In order to improve the quality of life of patients with the Ataxia disease, the biotechnological and pharmaceutical industry ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the process of definitive diagnosis through genetic testing, and the ...

a neurology professor at Harvard Medical School and the founding director of the Ataxia Center at Massachusetts General Hospital, said in a statement from Biohaven. Vlad Coric, Biohaven’s CEO ...

Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia Video content above is prompted by the following: Describe the typical clinical presentation of FA in terms of age of onset ...

Genetic analysis beyond the causative variants, and independent of the core clinical symptoms (pyramidal signs versus ataxia), might offer a more pertinent way to approach phenotypic variability.

Friedreich’s ataxia is a progressive neuromuscular disease that causes uncoordinated movement, muscle weakness, balance problems, impaired speech, and frequently, heart abnormalities.

Spinocerebellar ataxia is a group of dominantly inherited neurodegenerative disorders characterized by progressive loss of voluntary motor control and atrophy of the cerebellum, brainstem and ...

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting ...